Chubu University, Nagoya City University, Daiichi Sankyo, a major pharmaceutical company, and Mitsubishi UFJ Financial Group's venture capital, Mitsubishi UFJ Capital, have begun joint research on cancer hyperthermia. Continue joint research for 3 years, aiming to establish a new hyperthermia.
According to Chubu University, cancer hyperthermia focuses on the fact that cancer cells are more sensitive to heat than normal cells, and is a treatment method that kills only cancer cells by heating the cells.It is expected to be effective when used in combination with radiation therapy, chemotherapy, and immunotherapy.
In this hyperthermia research, we are developing a new device that can heat efficiently and aim to establish a safe and effective treatment method.From Chubu University, Professor Kaname Tsutsumi of the Faculty of Applied Biochemistry and Sakutaro Yamaguchi, Director of the Superconducting and Sustainable Energy Research Center, will participate.
A new company "Oideryoun" that promotes joint research was established in Chuo-ku, Tokyo in January, and the funds required for joint research will be fully invested by the Oide Fund Investment Limited Partnership operated by Mitsubishi UFJ Capital. ..
Daiichi Sankyo has positioned the cancer drug discovery sector as a priority field, and if it achieves its objectives in three years of research, it will purchase all the shares of Euderyoun and continue research and development as an in-house project.A certain amount of royalties will be paid to Chubu University and Nagoya City University when the target is achieved and after sales.
